Clinical Trial: Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07849803) titled 'Effect of Acoltremon Ophthalmic Solution 0.003% on Tear Production and Symptoms in Patients With Tear Deficiency and Concurrent Neuropathic Corneal Pain' on Sept. 24.

Brief Summary: This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production and ocular symptoms in participants with tear deficiency and concurrent neuropathic corneal pain. Acoltremon is formulated to help increase natural tear production by activating TRPM8 receptors on cold-sensitive corneal nerves. It is thought that this study treatment may help participants by increasing tear production while potentially redu...